Cargando…
Healthcare Costs and Resource Utilization in Patients with Infantile Spasms Treated with H.P. Acthar Gel(®)
INTRODUCTION: The purpose of this study was to describe healthcare resource utilization and costs resulting from early (within 30 days of diagnosis) versus late (>30 days after diagnosis) treatment with prescriptions for H.P. Acthar(®) Gel (repository corticotropin injection; Acthar; Mallinckrodt...
Autores principales: | Gold, Laura S., Schepman, Patricia B., Wang, Wei-Jhih, Philbin, Michael, Niewoehner, John, Damal, Kavitha, Hansen, Ryan N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4969327/ https://www.ncbi.nlm.nih.gov/pubmed/27324137 http://dx.doi.org/10.1007/s12325-016-0361-2 |
Ejemplares similares
-
Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®)
por: Gold, Laura S., et al.
Publicado: (2016) -
Direct effects of HP Acthar Gel(®) on human B lymphocyte activation in vitro
por: Olsen, Nancy J., et al.
Publicado: (2015) -
Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence
por: Wan, George J, et al.
Publicado: (2023) -
Cost-Effectiveness of Acthar Gel versus Standard of Care for the Treatment of Advanced Symptomatic Sarcoidosis
por: Bindra, Jas, et al.
Publicado: (2023) -
Corticosteroid Use and Adherence in Patients Treated with Acthar Gel for Advanced Sarcoidosis
por: Hayes, Kyle, et al.
Publicado: (2023)